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ABSTRACT
Introduction: Despite improvements in a range of
chemo, radio and surgical therapies, the overall
survival at 5 years from oesophago-gastric cancer
remains poor and ranges from 10% to 30%. Early
diagnosis is a key strategy to improve survival but early
disease stage has non-specific symptoms that are very
common while the warning clinical picture often
indicates advanced disease. The aim of this research is
to validate a breath test to predict oesophago-gastric
cancer therefore allowing earlier diagnosis and
introduction of treatment.
Methods and analysis: The study will include
325 patients and be conducted across four major
oesophago-gastric cancer centres in London, UK. This
research will utilise selected ion flow-tube mass
spectrometry (SIFT-MS) exhaled breath analysis, for
comparison of predicted cancer risk based on the
previously developed volatile organic compound
exhaled breath model, with endoscopic findings and
histology biopsies. This will determine the overall
diagnostic accuracy for non-invasive breath testing for
the diagnosis of oesophago-gastric cancer.
Ethics and Dissemination: Approval was gained
from NRES Committee London, on 16 July 2014 (REC
reference 14/LO/1136) for the completion of this study.
Different methods of dissemination will be employed
including international clinical and patient group
presentations, and publication of research outputs in a
high-impact clinical journal. This is to ensure that the
findings from this research will reach patients, primary
care practitioners, scientists, hospital specialists in
gastroenterology, oncology and surgery, health
policymakers and commissioners as well as NHS
regulatory bodies.
Trials registration number: UKCRN18063; Pre-
results.
INTRODUCTION
In the UK, upper gastrointestinal (GI) symp-
toms account for at least 3% of consultations
in primary care,1 and the national oesophago-
gastric (OG) cancer audit (2013) suggested
the number of patients per annum diagnosed
with OG cancer was approximately 11 500
with only 35% treated with a curative intent.2
Current UK referral guidelines for OG cancer
focus on alarm symptoms such as dysphagia
and odynophagia, despite these symptoms
having poor sensitivity and speciﬁcity for
cancer, and often only occurring in advanced
disease, translating into poor outcome and
overall survival. There is a wide range in the
rates of OG-duodenoscopy (OGD) per-
formed among general practice populations
in England, and it appears on average that
patients with OG cancer belonging to prac-
tices with the lowest rates of OGD performed
are at greater risk of poorer overall outcome.3
OGD remains the gold-standard investiga-
tion for the assessment of patients with upper
GI symptoms and considered at risk of OG
cancer. OGD is an expensive investigation,
uncomfortable for the patient, and not
without important risks including visceral per-
foration and bleeding. Furthermore, due to a
lack of clear guidance regarding the utilisation
of OGD, the identiﬁcation of OG cancer cur-
rently only occurs in 2% of all OGDs in the
UK,3 and often at a late and incurable stage.
Our group undertook a systematic review
to evaluate the clinical evidence for the util-
isation of volatile organic compound (VOC)
analysis from breath in the assessment of GI
disease.4 Eleven studies comprising 934
patients were included. Signiﬁcant differ-
ences in the VOC proﬁles from exhaled
breath of patients with gastro-oesophageal
cancer were observed, suggesting this may
have a future role as a non-invasive diagnostic
test. No studies reported any adverse events
associated with VOC breath analysis. Breath
analysis has been shown to be acceptable and
of diagnostic value in routine clinical practice
for the detection of Helicobacter Pylori5 and
intestinal bacterial overgrowth,6 and in the
diagnosis and assessment of asthma.7 8
Markar SR, et al. BMJ Open 2016;6:e009139. doi:10.1136/bmjopen-2015-009139 1
Open Access Protocol
Previous research undertaken by our group, using
selected-ion ﬂow-tube mass spectrometry (SIFT-MS),
demonstrated the presence of speciﬁc VOCs from the
headspace of urine and gastric content that were asso-
ciated with OG cancer.9 10 Following this, our group
focused research on the analysis of VOCs from exhaled
breath. In an initial pilot study, we found four VOCs that
signiﬁcantly differed between patients with cancer and
positive-control patients.11 We extended this initial
research to a larger cohort of 220 patients in whom we
developed a model based on the analysis of 12 VOCs
from exhaled breath, with a sensitivity of 84.6% and spe-
ciﬁcity of 76.1%, for the prediction of OG adenocarcin-
oma.12 Further work undertaken over the past year in a
follow-up cohort of 60 patients further reﬁned this diag-
nostic VOC breath model to nine VOCs (propanoic
acid, butyric acid, pentanoic acid, hexanoic acid, penta-
nal, heptanal, octanal, nonanal and decanal) from two
chemical groups (fatty acid and aldehyde) (sensitivity
95% and speciﬁcity 69%) with improved mechanistic
understanding of their derangement in OG adenocar-
cinoma. Previous research has identiﬁed speciﬁc VOC
breath signatures associated with lung, biliary tract and
head and neck cancers that do not overlap with the
nine VOCs that will be evaluated as part of the diagnos-
tic model for upper GI cancer in this study.13–16
In preparation for this multicentre study, we investi-
gated factors that inﬂuence the loss of target VOCs from
bags to eliminate time for transport between centres as a
confounding factor. Samples can be stored for up to
48 h at room temperature within GastroCHECK steel
breath bags with no evidence of loss of VOCs. We
further studied the variation seen in the concentration
of trace VOCs within ambient air, and demonstrated that
this may represent a confounding factor and must be
sampled regularly when undertaking multicentre breath
analysis. The next stage of this research and the subject
of this current proposal is to externally validate the
model for the prediction of OG cancer in a multicentre
setting.
Analysis of VOCs from breath provides a non-invasive
risk stratiﬁcation tool to identify high-risk patients who
should be referred for OGD at an earlier stage. This will
provide a more rational approach to the utilisation of
OGD and may allow earlier identiﬁcation of less invasive
and potentially curable cancer. The external validation
of this VOC breath model in a large multicentre study
will provide this risk-stratiﬁcation tool that triages the
patient to have endoscopy. The aim of this present study
is to determine the diagnostic accuracy of an exhaled
breath test in the prediction of OG cancer in a multicen-
tre blind validation study.
METHODS AND ANALYSIS
Main centre(s): St Mary’s, Royal Marsden Hospital,
Queens Romford and University College London
Hospitals, London, UK.
Design
▸ Inclusion criteria: Patients aged more than 18 years
with upper GI symptoms attending for endoscopy or
surgery. In the cancer cohort, only patients with non-
metastatic OG adenocarcinoma (stage I–III) will be
included.
▸ Exclusion criteria: Patients with a documented active
infection or known liver failure, and those unable to
provide informed consent or unable to provide a
500 mL breath sample.
▸ Intervention(s) or method
Breath sampling methodology: All patients will be asked to
sign a consent form to be included in this study (see
online supplementary appendix A), and will be given
an information leaﬂet (see online supplementary
appendices B and C). Patients will fast for a minimum
of 6 h prior to their breath sample collection. Patients
will rest in the same area for at least 20 min prior to
breath sampling and all breath samples will be
retrieved prior to endoscopy. Patients will be asked to
perform a single deep nasal inhalation followed by
complete exhalation via their mouth into a secure
GastroCHECK steel breath bag (500 mL) via a 1 mL
Luer-Lok syringe (Terumo Europe, Leuven, Belgium).
For each VOC measurement, the syringe plunger will
be removed from the 1 mL Luer-Lok syringe and the
GastroCHECK bag will be directly connected via the
syringe barrel to the sample inlet arm of the SIFT-MS
instrument. Patients with OG adenocarcinoma will be
sampled prior to the induction of neoadjuvant
therapy (neoadjuvant naïve).
VOC analysis using SIFT-MS: The principle of SIFT-MS
is as follows: selected precursor ions are formed in a
microwave discharge source and are selected accord-
ing to their mass-to-charge ratio, m/z, by a mass ﬁlter
and injected into a helium carrier gas where they are
convected as a thermalised swarm along a ﬂow tube.
H30+, NO+, O2+ precursor ions are used to ionise
the trace gases in an air sample that is introduced
into the helium at a known ﬂow rate; these ions
selectively ionise VOCs present within the sample,
resulting in characteristic product ions. By measuring
the count rate of both, precursor ions and the charac-
teristic product ions at the downstream detection
system, a real-time quantiﬁcation is achieved, realising
the absolute concentration of trace and volatile
compounds at the parts-per-billion by volume or
parts-per-million by volume. Samples will be analysed
using the multi-ion monitoring mode, selective VOCs
from breath will be analysed for a total of 60 s and
measured concentrations will be averaged over this
time for each VOC.
▸ End point: The diagnostic accuracy of the exhaled
breath test for the prediction of OG cancer.
Quality assurance
▸ Calibration to water: The concentration of water in
human breath is approximately 6%. All samples will
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be tested using SIFT-MS to ensure that the percent-
age of water from the exhaled breath sample within
the bag is between 5% and 6.5%. If this is not the
case the sample will be discarded as it is likely to be
unreliable.
▸ Ambient room air: Weekly samples will be taken from
the ambient room air at the different hospitals where
patients are being breath sampled and also from the
laboratory air where samples are analysed. This is to
ensure that there is no contamination from the
ambient room air to cause anomalous results; con-
tamination represents an important confounding
factor that must be measured.
▸ Standardisation of breath sampling methodology:
Human factor analysis previously undertaken by our
group has shown several potential sources of error in
breath sampling that can affect the results of analysis.
All clinicians and researchers participating in this
clinical trial will go through a credentialing process
involving observation of consent, performing breath
sampling and storage of samples, prior to inclusion in
the study.
▸ Cross-platform validation: In a subset of 50 patients,
an additional breath sample will be taken and analysed
using Thermal Desorption Gas Chromatography
Mass Spectrometry (TD-GC-MS). This analytical
technique allows accurate compound identiﬁcation,
with SIFT-MS permitting accurate compound
quantiﬁcation.
▸ Data monitoring committee: Professor David Smith FRS
(University of Keele, UK) and Professor Patrik Spanel
( J Heyrovsky Institute of Physical Chemistry, Prague,
Czech Republic) will provide independent data moni-
toring of the quality of breath analysis results obtained.
Both are experts in the ﬁeld of breath analysis and
selected-ion ﬂow-tube mass spectrometry (SIFT-MS).
Professor Jasper Lagergren (Karolinska Institutet,
Stockholm, Sweden) will monitor clinical data.
Statistical analysis and plan, including:
▸ Sample size and power calculations: Based on 50% of
patients in the study population having cancer (one
benign patient will be recruited to one patient with
cancer) and maintaining a sensitivity and speciﬁcity
of 80% for the diagnostic model derived from our
previous research, the sample size estimated for the
multicentre external validation study is 325 patients;
162 patients with oesophageal or gastric cancer and
163 patients with benign conditions or a normal
upper GI tract. From previous research undertaken, it
is anticipated that 5% of patients recruited are likely
to be withdrawn due to inconsistencies in breath sam-
pling technique and transport. Therefore, the target
recruitment for this study is 342 patients; 171 with
oesophageal or gastric cancer and 171 with benign
conditions or a normal upper GI tract. This sample
size calculation was performed by Asif Johar,
Statistician, Karolinska Institutet, Stockholm, Sweden.
▸ Statistical tests: Comparison of predicted cancer risk
and actual OGD ﬁndings or histology from endo-
scopic biopsies (gold standard) will then be made,
and the overall diagnostic accuracy (sensitivity, speciﬁ-
city, positive and negative predictive value, receiver
operator curve analysis) for this non-invasive diagnos-
tic investigation will be determined. Potential con-
founding factors across the study groups will be
evaluated by employing the Kruskal-Wallis test for
continuous variables and χ2 test for discrete variables.
Linear regression models will be used to assess any
inﬂuence of patient demographic factors, or medica-
tions (this data will be collected using the Case
Report Form online supplementary appendix d) on
VOC concentrations measured.
▸ Blind analysis: OGD ﬁndings with or without hist-
ology from endoscopic biopsies will provide the gold
standard against which the results of the breath ana-
lysis model will be tested. Data will be sent to Fredrik
Mattsson, senior biostatistician in Jesper Lagergren’s
group at Karolinska Institutet, Stockholm, Sweden,
who will be blinded to the results of the OGD and
histology, and he will generate the predicted cancer
risk using the model previously developed and based
solely on breath analysis results gained. Comparison
of predicted cancer risk and actual OGD ﬁndings or
histology from endoscopic biopsies will then be
made.
Ethics
▸ Ethics committee approval: NHS Health Research
Authority (NRES Committee London—Camden and
Islington) approval gained on 16 July 2014 (REC ref-
erence 14/LO/1136).
▸ Interim analyses and stopping rules: No interim ana-
lysis will be performed, and the data will analysed
when the target recruitment of 325 patients has been
reached.
DISSEMINATION
Different methods of dissemination will be employed so
that the ﬁndings from this research will reach patients,
primary care practitioners, scientists, hospital specialists
in gastroenterology, oncology and surgery, health policy-
makers and commissioners as well as NHS regulatory
bodies. We plan to present the ﬁndings of this
research at international gastroenterology, oncology and
surgical research meetings. We will also present the
ﬁndings of this research to relevant patient groups
including NIHR-INVOLVE and the Oesophageal Patient
Association. Following generation and validation of this
robust model for the prediction of OG cancer, we plan
to publish the results of this research in a high impact
factor clinical journal to allow widespread dissemination
of this research.
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